鷺燕醫藥(002788.SZ):目前公司下屬兩家中藥飲片生產企業都在擴大規模
格隆匯6月8日丨有投資者向鷺燕醫藥(002788.SZ)提問:中藥飲片的年產值及未來的規劃?
鷺燕醫藥回覆:中藥飲片的市場,未來會同西藥的趨勢一樣。集採的品種和規模越來越大。剛結束的中藥飲片省際聯盟集採就是這個趨勢的反映。隨着中藥飲片的監管越來越嚴、市場越來越規範,市場中原有的小生產企業生存壓力變大,有規模效應、管理規範的生產企業將獲得更大的市場份額。目前公司下屬兩家中藥飲片生產企業都在擴大規模,提升市場佔有率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.